Research programme: integrin inhibitors - 3B Pharmaceuticals

Drug Profile

Research programme: integrin inhibitors - 3B Pharmaceuticals

Alternative Names: JSM-8757

Latest Information Update: 26 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jerini
  • Developer 3B Pharmaceuticals
  • Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Integrin alpha 5 beta 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 13 Jan 2014 Preclinical development is ongoing for Solid tumours in Germany
  • 19 Mar 2010 Preclinical development is ongoing in Germany
  • 31 Dec 2009 3B Pharmaceuticals acquires R&D assets of Jerini AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top